Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

Key facts

Sponsor

Avidity Biosciences, Inc.

Intervention

Del-desiran (AOC 1001)(drug)

Enrollment

230 enrolled

Eligibility

16 years · All sexes

Timeline

2025 – 2030

Study locations (20)

• University of California, Los Angeles (UCLA), Los Angeles, California, United States
• Stanford University, Stanford, California, United States
• University of Colorado, Denver, Colorado, United States
• University of Florida, Gainesville, Florida, United States
• Indiana University (IU), Indianapolis, Indiana, United States
• Kansas University Medical Center, Kansas City, Kansas, United States
• Kennedy Krieger Institute, Baltimore, Maryland, United States
• Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
• University of Rochester Medical Center, Rochester, New York, United States
• Duke University Medical Center, Durham, North Carolina, United States
• Ohio State University, Columbus, Ohio, United States
• University of Pennsylvania, Philadelphia, Pennsylvania, United States
• Houston Methodist Neurological Institute, Houston, Texas, United States
• Virginia Commonwealth University, Richmond, Virginia, United States
• The Ottawa Hospital, Ottawa, Ontario, Canada
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Thomsen and Becker disease

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE3NCT06411288
  Global Study of Del-desiran for the Treatment of DM1
  Avidity Biosciences, Inc.

See all trials for Thomsen and Becker disease →